Muscle MRS detects elevated PDE/ATP ratios prior to fatty infiltration in Becker muscular dystrophy

NMR in Biomedicine

Volumn 27, Issue 11, 2014, Pages 1371-1377

  Wokke, B H ^a   Hooijmans, M T ^a   van den Bergen, J C ^a   Webb, A G ^a   Verschuuren, J J ^a   Kan, H E ^a  

^a LEIDEN UNIVERSITY MEDICAL CENTER   (Netherlands)

Author keywords

Becker muscular dystrophy; MRS; PDE; Phosphor spectroscopy

Indexed keywords

BIOMOLECULES; METABOLISM; METABOLITES;

DISEASE PROCESS; HEALTHY CONTROLS; METABOLIC CHANGES; METABOLITE LEVEL; MR SCANNERS; MUSCLE WEAKNESS; MUSCULAR DYSTROPHY; SKELETAL MUSCLE;

MUSCLE;

ADENOSINE TRIPHOSPHATE; DMD PROTEIN, HUMAN; DYSTROPHIN; GLYCEROL 3-PHOSPHOETHANOLAMINE; GLYCEROPHOSPHOLIPID; GLYCEROPHOSPHORYLCHOLINE; PHOSPHORUS; PROTON;

ADULT; AGED; ARTICLE; BECKER MUSCULAR DYSTROPHY; CLINICAL ARTICLE; COMPARATIVE STUDY; CONTROLLED STUDY; FATTY LIVER; FEMALE; GASTROCNEMIUS MUSCLE; HUMAN; LIMIT OF QUANTITATION; MALE; MATHEMATICAL PARAMETERS; MIDDLE AGED; MUSCLE METABOLISM; NUCLEAR MAGNETIC RESONANCE IMAGING; NUCLEAR MAGNETIC RESONANCE SCANNER; OUTCOME ASSESSMENT; PERONEUS MUSCLE; PHOSPHATE METABOLISM; PHOSPHODIESTER ADENOSINE TRIPHOSPHATE RATIO; PHOSPHORUS NUCLEAR MAGNETIC RESONANCE; QUANTITATIVE ANALYSIS; SIGNAL NOISE RATIO; SKELETAL MUSCLE; SOLEUS MUSCLE; TIBIALIS ANTERIOR MUSCLE; ADIPOSE TISSUE; CASE CONTROL STUDY; CHEMISTRY; DISABILITY; DISEASE COURSE; DNA MUTATIONAL ANALYSIS; DUCHENNE MUSCULAR DYSTROPHY; GENETICS; METABOLISM; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PATHOLOGY; PROCEDURES; YOUNG ADULT;

ADENOSINE TRIPHOSPHATE; ADIPOSE TISSUE; ADULT; AGED; CASE-CONTROL STUDIES; DISABILITY EVALUATION; DISEASE PROGRESSION; DNA MUTATIONAL ANALYSIS; DYSTROPHIN; FEMALE; GLYCEROPHOSPHOLIPIDS; GLYCERYLPHOSPHORYLCHOLINE; HUMANS; MAGNETIC RESONANCE IMAGING; MAGNETIC RESONANCE SPECTROSCOPY; MIDDLE AGED; MUSCLE, SKELETAL; MUSCULAR DYSTROPHY, DUCHENNE; PHOSPHORUS ISOTOPES; PROTONS; YOUNG ADULT;

EID: 84911212022     PISSN: 09523480     EISSN: 10991492     Source Type: Journal    
DOI: 10.1002/nbm.3199     Document Type: Article

References (43)

1. Hoffman EP, Brown RH, Jr, Kunkel LM. Dystrophin: the protein product of the Duchenne muscular dystrophy locus. Cell 1987; 51(6): 919-928.
2. McDouall RM, Dunn MJ, Dubowitz V. Nature of the mononuclear infiltrate and the mechanism of muscle damage in juvenile dermatomyositis and Duchenne muscular dystrophy. J. Neurol. Sci. 1990; 99(2/3): 199-217.
3. Petrof BJ, Shrager JB, Stedman HH, Kelly AM, Sweeney HL. Dystrophin protects the sarcolemma from stresses developed during muscle contraction. Proc. Natl. Acad. Sci. U. S. A. 1993; 90(8): 3710-3714.
4. Beggs AH, Hoffman EP, Snyder JR, Arahata K, Specht L, Shapiro F, Angelini C, Sugita H, Kunkel LM. Exploring the molecular basis for variability among patients with Becker muscular dystrophy: dystrophin gene and protein studies. Am. J. Hum. Genet. 1991; 49(1): 54-67.
5. Comi GP, Prelle A, Bresolin N, Moggio M, Bardoni A, Gallanti A, Vita G, Toscano A, Ferro MT, Bordoni A, Fortunato F, Ciscato P, Felisari G, Tedeschi S, Castelli E, Garghentino R, Turconi A, Fraschini P, Marchi E, Negretto GG, Adobbati L, Meola G, Tonin P, Papadimittiou A, Scarlato G. Clinical variability in Becker muscular dystrophy. Genetic, biochemical and immunohistochemical correlates. Brain 1994; 117(Pt 1): 1-14.
6. Anthony K, Cirak S, Torelli S, Tasca G, Feng L, Arechavala-Gomeza V, Armaroli A, Guglieri M, Straathof CS, Verschuuren JJ, Aartsma-Rus A, Helderman-van den Enden P, Bushby K, Straub V, Sewry C, Ferlini A, Ricci E, Morgan JE, Muntoni F. Dystrophin quantification and clinical correlations in Becker muscular dystrophy: implications for clinical trials. Brain 2011; 134(Pt 12): 3547-3559.
7. Bushby KM, Gardner-Medwin D, Nicholson LV, Johnson MA, Haggerty ID, Cleghorn NJ, Harris JB, Bhattacharya SS. The clinical, genetic and dystrophin characteristics of Becker muscular dystrophy. II. Correlation of phenotype with genetic and protein abnormalities. J. Neurol. 1993; 240(2): 105-112.
8. Van den Bergen JC, Wokke BH, Janson AA, van Duinen SG, Hulsker MA, Ginjaar HB, van Deutekom JC, Aartsma-Rus A, Kan HE, Verschuuren JJ. Dystrophin levels and clinical severity in Becker muscular dystrophy patients. J. Neurol. Neurosurg. Psychiatry. DOI: 10.1136/jnnp2013-306350
9. Nicholson LV, Johnson MA, Bushby KM, Gardner-Medwin D, Curtis A, Ginjaar IB, den Dunnen JT, Welch JL, Butler TJ, Bakker E, van Ommen GJ, Harris JB. Integrated study of 100 patients with Xp21 linked muscular dystrophy using clinical, genetic, immunochemical, and histopathological data. Part 2. Correlations within individual patients. J. Med. Genet. 1993; 30(9): 737-744.
10. Pegoraro E, Hoffman EP, Piva L, Gavassini BF, Cagnin S, Ermani M, Bello L, Soraru G, Pacchioni B, Bonifati MD, Lanfranchi G, Angelini C, Kesari A, Lee I, Gordish-Dressman H, Devaney JM, McDonald CM, Cooperative International Neuromuscular Research Group. SPP1 genotype is a determinant of disease severity in Duchenne muscular dystrophy. Neurology 2011; 76(3): 219-226.
11. Tasca G, Iannaccone E, Monforte M, Masciullo M, Bianco F, Laschena F, Ottaviani P, Pelliccioni M, Pane M, Mercuri E, Ricci E. Muscle MRI in Becker muscular dystrophy. Neuromuscul. Disord. 2012; 22(Suppl. 2): S100-S106.
12. Kemp GJ, Taylor DJ, Dunn JF, Frostick SP, Radda GK. Cellular energetics of dystrophic muscle. J. Neurol. Sci. 1993; 116(2): 201-206.
13. 31P magnetic resonance spectroscopy study. Brain 1999; 122(Pt 1): 121-130.
14. Barbiroli B, Funicello R, Iotti S, Montagna P, Ferlini A, Zaniol P. 31P-NMR spectroscopy of skeletal muscle in Becker dystrophy and DMD/BMD carriers. Altered rate of phosphate transport. J. Neurol. Sci. 1992; 109(2): 188-195.
15. Tosetti M, Linsalata S, Battini R, Volpi L, Cini C, Presciutti O, Muntoni F, Cioni G, Siciliano G. Muscle metabolic alterations assessed by 31-phosphorus magnetic resonance spectroscopy in mild Becker muscular dystrophy. Muscle Nerve 2011; 44(5): 816-819.
16. Newman RJ. An in vivo study of muscle phosphate metabolism in Becker's dystrophy by 31P NMR spectroscopy. Metabolism 1985; 34(8): 737-740.
17. Crilley JG, Boehm EA, Rajagopalan B, Blamire AM, Styles P, Muntoni F, Hilton-Jones D, Clarke K. Magnetic resonance spectroscopy evidence of abnormal cardiac energetics in Xp21 muscular dystrophy. J. Am. Coll. Cardiol. 2000; 36(6): 1953-1958.
18. Gladstone JN, Bishop JY, Lo IK, Flatow EL. Fatty infiltration and atrophy of the rotator cuff do not improve after rotator cuff repair and correlate with poor functional outcome. Am. J. Sports Med. 2007; 35(5): 719-728.
19. 31P MRS study. Magn. Reson. Imaging 2010; 28(5): 698-707.
20. Di Marzo L, Sapienza P, Tedesco M, Mingoli A, Capuani G, Aureli T, Giuliani A, Conti F, Cavallaro A. 31Phosphorus magnetic resonance spectroscopy to evaluate medical therapy efficacy in peripheral arterial disease. A pilot study. Panminerva Med. 1999; 41(4): 283-290.
21. Argov Z, Renshaw PF, Boden B, Winokur A, Bank WJ. Effects of thyroid hormones on skeletal muscle bioenergetics. In vivo phosphorus-31 magnetic resonance spectroscopy study of humans and rats. J. Clin. Invest. 1988; 81(6): 1695-1701.
22. Webb AG, Smith NB, Aussenhofer S, Kan HE. Use of tailored higher modes of a birdcage to design a simple double-tuned proton/phosphorus coil for human calf muscle studies at 7 T. Concepts Magn. Reson. 2011; 39B(2): 89-97.
23. Schar M, Kozerke S, Fischer SE, Boesiger P. Cardiac SSFP imaging at 3 Tesla. Magn. Reson. Med. 2004; 51(4): 799-806.
24. 31P relaxation times in the human calf muscle: a comparison between 3 T and 7 T in vivo. Magn. Reson. Med. 2009; 62(3): 574-582.
25. Taylor DJ, Bore PJ, Styles P, Gadian DG, Radda GK. Bioenergetics of intact human muscle. A 31P nuclear magnetic resonance study. Mol. Biol. Med. 1983; 1(1): 77-94.
26. Wokke BH, Bos C, Reijnierse M, van Rijswijk CS, Eggers H, Webb A, Verschuuren JJ, Kan HE. Comparison of dixon and T1-weighted MR methods to assess the degree of fat infiltration in duchenne muscular dystrophy patients. J. Magn. Reson. Imaging 2013; 38(3): 619-624.
27. Burt CT, Glonek T, Barany M. Phosphorus-31 nuclear magnetic resonance detection of unexpected phoshpodiesters in muscle. Biochemistry 1976; 15(22): 4850-4853.
28. Ruiz-Cabello J, Cohen JS. Phospholipid metabolites as indicators of cancer cell function. NMR Biomed. 1992; 5(5): 226-233.
29. Satrustegui J, Berkowitz H, Boden B, Donlon E, McLaughlin A, Maris J, Warnell R, Chance B. An in vivo phosphorus nuclear magnetic resonance study of the variations with age in the phosphodiester content of human muscle. Mech. Ageing Dev. 1988; 42(2): 105-114.
30. Szendroedi J, Schmid AI, Chmelik M, Krssak M, Nowotny P, Prikoszovich T, Kautzky-Willer A, Wolzt M, Waldhausl W, Roden M. Skeletal muscle phosphodiester content relates to body mass and glycemic control. PLoS One 2011; 6(7): e21846.
31. Burt CT. Phosphodiesters and NMR: a tale of rabbits and chickens. Trends Biochem. Sci. 1985; 10: 404-406.
32. Fallbrook A, Turenne SD, Mamalias N, Kish SJ, Ross BM. Phosphatidylcholine and phosphatidylethanolamine metabolites may regulate brain phospholipid catabolism via inhibition of lysophospholipase activity. Brain Res. 1999; 834(1/2): 207-210.
33. 31P-magnetic resonance spectroscopy study. Cancer Res. 2001; 61(20): 7536-7543.
34. Webster C, Silberstein L, Hays AP, Blau HM. Fast muscle fibers are preferentially affected in Duchenne muscular dystrophy. Cell 1988; 52(4): 503-513.
35. 31P NMR anomalies of skeletal muscle metabolites in canine muscular dystrophy. NMR Biomed. 2012; 25(10): 1160-1169.
36. 31P NMR studies in Duchenne muscular dystrophy: age-related metabolic changes. Neurology 1987; 37(1): 165-169.
37. 31P-MR spectroscopy study. Muscle Nerve 1992; 15(3): 344-348.
38. Johnson MA, Polgar J, Weightman D, Appleton D. Data on the distribution of fibre types in thirty-six human muscles. An autopsy study. J. Neurol. Sci. 1973; 18: 111-129.
39. Taylor DJ, Kemp GJ, Thompson CH, Radda GK. Ageing: effects on oxidative function of skeletal muscle in vivo. Mol. Cell. Biochem. 1997; 174(1/2): 321-324.
40. Kan HE, Klomp DW, Wohlgemuth M, van Loosbroek-Wagemans I, van Engelen BG, Padberg GW, Heerschap A. Only fat infiltrated muscles in resting lower leg of FSHD patients show disturbed energy metabolism. NMR Biomed. 2010; 23(6): 563-568.
41. Bernus G, Gonzalez de Suso JM, Alonso J, Martin PA, Prat JA, Arus C. 31P-MRS of quadriceps reveals quantitative differences between sprinters and long-distance runners. Med. Sci. Sports Exerc. 1993; 25(4): 479-484.
42. Argov Z, Lofberg M, Arnold DL. Insights into muscle diseases gained by phosphorus magnetic resonance spectroscopy. Muscle Nerve 2000; 23(9): 1316-1334.
43. Kemp GJ, Manners DN, Clark JF, Bastin ME, Radda GK. A theoretical model of some spatial and temporal aspects of the mitochondrion creatine kinase myofibril system in muscle. Mol. Cell. Biochem. 1997; 174(1/2): 29-32.